SELLAS Life Sciences (SLS) Divestments (2015 - 2016)
SELLAS Life Sciences (SLS) posted quarterly Divestments of -$1.0 million for Q1 2016, down 110.0% year-over-year from $10.5 million in Q2 2015, and down 109.31% quarter-over-quarter from $11.3 million in Q4 2015.
SELLAS Life Sciences (SLS) Divestments (2015 - 2016) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Divestments for 2 consecutive years, with -$1.0 million the latest figure, recorded in Q1 2016.
- In Q1 2016, Divestments fell 110.0% year-over-year to -$1.0 million; the TTM figure through Dec 2016 stood at -$1.0 million (down 109.77% YoY), while the FY2016 annual figure was -$1.0 million, down 109.77% from the prior year.
- Divestments retreated to -$1.0 million in Q1 2016 per SLS's latest filing, from $11.3 million in the prior quarter.
- Across five years, Divestments topped out at $11.3 million in Q4 2015 and bottomed at -$1.0 million in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 9.82 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -13.21 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -1.05 Mn |
| Dec 31, 2015 | 11.28 Mn |
| Jun 30, 2015 | -34,000.00 |
| Mar 31, 2015 | -500,000.00 |